Symbicort Single Inhaler Therapy vs Conventional Best Practice for the Treatment of Persistent Asthma in Adults
Status:
Terminated
Trial end date:
2008-10-01
Target enrollment:
Participant gender:
Summary
This study is intended to extend the knowledge of Symbicort Single Inhaler Therapy into a
more general setting in order to assess the real-life impact of introducing this new
treatment concept. The study will compare the Symbicort Single Inhaler Therapy concept with a
conventional stepwise treatment regimen according to the investigator's judgement in patients
who present with symptoms on inhaled glucocorticosteroids (GCS) treatment or who require and
are already on treatment with a combination of inhaled and long-acting B2 agonists (LABA).
Phase:
Phase 3
Details
Lead Sponsor:
AstraZeneca
Treatments:
Budesonide Budesonide, Formoterol Fumarate Drug Combination Formoterol Fumarate